How much does one targeted treatment with Osimertinib/Tarisso cost?

Osimertinib/Tagrisso (Osimertinib) contains the active substance osimertinib and is a drug that treats lung cancer, called non-small cell lung cancer (NSCLC). It is used alone to help patients whose cancer cells have specific mutations in the gene for a protein called EGFR, including: The drug is given to patients whose cancer cells have a genetic change called Ex19del or L858R, and their cancer has not spread to other organs and has been completely removed with surgery. To prevent cancer recurrence (adjuvant treatment); or if the patient's cancer cells have mutations called "activating mutations" and their cancer has entered an advanced stage or has spread, osimertinib will be used as the first treatment option; or for patients whose cancer cells have the T790M mutation and their cancer is advanced or has spread, it can be given after other treatments.

The original drug Osimertinib has been launched in the domestic market. Its conventional packaging includes 80mg 30 tablets and 40mg 30 tablets. Each box is sold for approximately RMB 4,000 to 6,000 yuan. Fortunately, osimertinib has now been included in the medical insurance list, and patients can enjoy preferential policies for medical insurance reimbursement, thus effectively alleviating the financial pressure caused by treatment.

At the same time, the overseas version of the original osimertinib drug may be priced as high as more than 10,000 US dollars per box, which is expensive. However, there are also generic drugs available in overseas markets, and the ingredients of these generic drugs are basically the same as the original drugs. For example, the 80mg*30 tablets produced by pharmaceutical factories in countries such as Laos and Bangladesh cost only about RMB 800 per box (the price may fluctuate due to exchange rate changes), which is relatively more economical.